Royalty Pharma to present at UBS Global Biopharma Conference on Nov 17, 2026

Royalty Pharma plc announced it will participate in a fireside chat at the UBS Global Biopharma Conference on November 17, 2026. The event will be webcast and accessible via Royalty Pharma's website. As the largest buyer of biopharmaceutical royalties, Royalty Pharma funds innovation by acquiring royalties and co-funding clinical trials. This presentation highlights the company's ongoing role in the biopharma industry and offers investors insight into its portfolio and strategy.

Royalty Pharma plc holds a market cap of $31.16 billion and offers a dividend yield of 1.34% as of November 13, 2026, 04:11 WIB. On Pluang, its shares trade at USD 68.76 with a 1-day decline of 1.79%, reflecting active investor interest with a volume of 3,532,759 shares. This positioning underscores the company's significant role in the biopharma sector as it prepares for its upcoming presentation at the UBS Global Biopharma Conference.